Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial

Sugiyama, Toru; Okamoto, Aikou; Enomoto, Takayuki; Hamano, Tetsutaro; Aotani, Eriko; Terao, Yasuhisa; Suzuki, Nao; Mikami, Mikio; Yaegashi, Nobuo; Kato, Kanefusa; Yoshikawa, Hiroyuki; Yokoyama, Yoshihiko; Tanabe, Hiroshi; Nishino, Kazumi; Nomura, Hiroyuki; Kim, Jae Weon; Kim, Byoung Gie; Pignata, Sandro; Alexandre, Jérôme; Green, John; Isonishi, Seiji; Terauchi, Fumitoshi; Fujiwara, Keiichi; Aoki, Daisuke

doi:10.1200/jco.2016.66.9010

Cited by 117 publications

(93 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lastly, contrary to the expectations from the promising results of the previous randomized phase II study (JGOG3014) [34], which showed a tendency of PFS superiority of the irinotecan plus cisplatin group compared with paclitaxel plus carboplatin group in a subset analysis of ovarian clear cell carcinoma (CCC) patients without residual disease or with residual disease <2 cm, a randomized phase III trial of irinotecan plus cisplatin compared with paclitaxel plus carboplatin as first-line chemotherapy for CCC (JGOG3017) failed to show significant survival benefit between the groups [35]. In this study, a total of 667 ovarian CCC patients were randomized to receive irinotecan 60 mg/m 2 (day 1, 8, and 15) plus cisplatin 60 mg/m 2 (day 1) every 4 weeks or paclitaxel 175 mg/m 2 plus carboplatin AUC 6 every 3 weeks.…”

Section: Ovarian Cancermentioning

confidence: 99%

Major clinical research advances in gynecologic cancer in 2016: 10-year special edition

Suh

Kim

et al. 2017

J Gynecol Oncol

Self Cite

View full text Add to dashboard Cite

In 2016, 13 topics were selected as major research advances in gynecologic oncology. For ovarian cancer, study results supporting previous ones regarding surgical preventive strategies were reported. There were several targeted agents that showed comparable responses in phase III trials, including niraparib, cediranib, and nintedanib. On the contrary to our expectations, dose-dense weekly chemotherapy regimen failed to prove superior survival outcomes compared with conventional triweekly regimen. Single-agent non-platinum treatment to prolong platinum-free-interval in patients with recurrent, partially platinum-sensitive ovarian cancer did not improve and even worsened overall survival (OS). For cervical cancer, we reviewed robust evidences of larger-scaled population-based study and cost-effectiveness of nonavalent vaccine for expanding human papillomavirus (HPV) vaccine coverage. Standard of care treatment of locally advanced cervical cancer (LACC) was briefly reviewed. For uterine corpus cancer, new findings about appropriate surgical wait time from diagnosis to surgery were reported. Advantages of minimally invasive surgery over conventional laparotomy were reconfirmed. There were 5 new gene regions that increase the risk of developing endometrial cancer. Regarding radiation therapy, Post-Operative Radiation Therapy in Endometrial Cancer (PORTEC)-3 quality of life (QOL) data were released and higher local control rate of image-guided adaptive brachytherapy was reported in LACC. In addition, 4 general oncology topics followed: chemotherapy at the end-of-life, immunotherapy with reengineering T-cells, actualization of precision medicine, and artificial intelligence (AI) to make personalized cancer therapy real. For breast cancer, adaptively randomized trials, extending aromatase inhibitor therapy, and ribociclib and palbociclib were introduced.

show abstract

Section: Ovarian Cancermentioning

confidence: 99%

Major clinical research advances in gynecologic cancer in 2016: 10-year special edition

Suh

Kim

et al. 2017

J Gynecol Oncol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Irinotecan hydrochloride, inhibiting topoisomerase I, is one of the key anticancer drugs in chemotherapy for several cancers such as colorectal cancer, lung cancer, gastric cancer, and gynecologic cancers 1–4. The patients treated with irinotecan occasionally experience severe neutropenia and delayed diarrhea; however, the occurrence of these adverse reactions has been unpredictable and largely unexplained 5.…”

Section: Introductionmentioning

confidence: 99%

UGT1A1 polymorphisms in cancer: impact on irinotecan treatment

Takano¹,

Sugiyama²

2017

PGPM

Self Cite

View full text Add to dashboard Cite

Mutations in the UGT1A1 gene have been implicated in Gilbert syndrome, which shows mild hyperbilirubinemia, and a more aggressive childhood subtype, Crigler–Najjar syndrome. To date, more than 100 variants have been found in the UGT1A1 gene. Among them, UGT1A1*28 and UGT1A1*6 have been reported to be associated with severe toxicities in patients treated with irinotecan-based chemotherapy by increasing the dose of SN-38 (7-ethyl-10-hydroxycamptothecin), an active form of irinotecan. Many association studies and meta-analyses have demonstrated the contribution of UGT1A1*28 and UGT1A1*6 polymorphisms to the toxicities caused by irinotecan-based therapy. The aim of this review was to evaluate the impact of these variants upon the toxicities and the efficacy of irinotecan-based chemotherapy.

show abstract

“…3Y5 A recent randomized phase III clinical trial comparing the efficacy of irinotecan plus cisplatin to that of paclitaxel plus carboplatin in patients with OCCC [Japanese Gynecologic Oncology Group (JGOG) 3017/ Gynecologic Cancer Intergroup (GCIG) Trial] failed to observe a significant survival benefit with irinotecan plus cisplatin. 6 Therefore, effective and novel treatment strategies, such as incorporation of molecular-targeted agents to current protocols, are urgently needed to improve outcomes for patients with advanced OCCC.…”

mentioning

confidence: 99%

Inhibition of Aurora Kinase A Synergistically Enhances Cytotoxicity in Ovarian Clear Cell Carcinoma Cell Lines Induced by Cisplatin

Chiba

Sato

Itamochi³

et al. 2017

International Journal of Gynecological Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial

Abstract: No significant survival benefit was found for CPT-P. Both regimens were well tolerated, but the toxicity profiles differed significantly. Treatment with existing anticancer agents has limitations to improving the prognosis of CCC.

Cited by 117 publications

References 29 publications

Major clinical research advances in gynecologic cancer in 2016: 10-year special edition

Major clinical research advances in gynecologic cancer in 2016: 10-year special edition

UGT1A1 polymorphisms in cancer: impact on irinotecan treatment

Inhibition of Aurora Kinase A Synergistically Enhances Cytotoxicity in Ovarian Clear Cell Carcinoma Cell Lines Induced by Cisplatin

Contact Info

Product

Resources

About